New book by Larry Connors Click here Improve your trading - See how
The corrected release reads:
AVILA THERAPEUTICS APPOINTS DANIEL S. LYNCH AS EXECUTIVE CHAIRMAN
Former ImClone Systems CEO Brings Corporate Strategy, Operations Expertise
Avila Therapeutics, a biotechnology company developing a novel class of small molecule drugs, known as covalent drugs, that treat diseases through protein silencing, announced today the appointment of Daniel S. Lynch as executive chairman to Avila's board of directors. In this role, Mr. Lynch will be actively involved in guiding Avila's strategy and directing the company's product development plans for novel covalent drugs. Mr. Lynch brings more than 20 years of experience serving in management positions in the biotechnology and pharmaceutical industries.
Mr. Lynch spent nearly five years at ImClone Systems, serving as Chief Executive Officer and Chief Financial Officer. As CEO, Mr. Lynch led ImClone through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of ERBITUX(R) (Cetuximab), a novel cancer treatment. As CFO, Mr. Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Mr. Lynch served in various financial positions at Bristol-Myers Squibb during a 15-year tenure. He is currently a director of several drug development companies including Ivrea Pharmaceuticals, Stromedix, and U.S. Oncology.
"We are delighted to welcome Dan to the role of Executive Chairman of Avila," said Michael F. Bigham, board of directors' member of Avila and partner at Abingworth Management, Avila's lead investor. "Dan's expertise in corporate strategy, operations and business development will be a valuable asset to Avila. His proven abilities to manage novel technologies through clinical development and to drive sound partnering arrangements are natural complements to the existing Avila team."
"Avila stands out as a biotech company with strong potential to rapidly develop a novel class of small molecule drugs for important diseases such as cancer, hepatitis C and inflammation. This potential comes from Avila's unique and powerful platform for developing covalent drugs that can completely silence disease-causing proteins, with superior properties to existing drugs," said Mr. Lynch. "Avila has a highly talented team, an emerging pipeline of promising drug candidates, the backing of premier investors and the vision and commitment to deliver novel products for patients."
Mr. Lynch holds an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia and a bachelor of arts in mathematics from Wesleyan University.
About Avila Therapeutics
Avila Therapeutics is developing a whole new therapeutic approach called 'protein silencing' based on a proprietary platform for developing covalent drugs that strongly and resiliently bond to disease-causing proteins, resulting in drugs that can be highly effective against diseases. Avila's covalent drugs have unique therapeutic benefits because they are highly targeted, are effective against mutations, and have long duration of action. Avila is developing a pipeline of novel, protein silencing drugs with a current focus on viral infection, cancer, and autoimmune diseases. Avila was founded in 2007 and is based in Waltham, Massachusetts. For additional information, please visit http://www.avilatx.com.
SOURCE: Avila Therapeutics
Yates Public Relations Kathryn Morris, 914-204-6412
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
